Prospective, open label, randomized, multi-centre, study to compare the safety, tolerability and effectiveness of topical Minoxidil 5% solution (cetosomal versus conventional), in Indian male patients with mild to moderate Patterned Hair Loss(PHL)

Hairrevive Centre for Hair Restoration Skin Rejuvenation0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Adult male patients of PHL of mild-moderate severity (BASP grading)
•Patients willing to refrain from other forms of treatment including other topical, oral medication for hair loss, laser treatments, injectable treatments and hair transplantation for the duration of study
•Patients who are willing to appear for regular follow ups and follow the prescribed treatment regularly
•Patients who are willing to give consent to participate in the study

•1.Patients suffering from other causes of non-cicatricial alopecia or cicatricial alopecia.
•2.Patients suffering from infectious, auto-immune, or other disorders affecting skin of scalp.
•3.Patients suffering from severe PHL, BASP scale M3, C2, C3, U1, U2, U3, V2, V3, F2, and F3 were recorded as â??severeâ?? and excluded from the study.
•4.Documented and known history of severe systemic disease, necessitating medical treatment, as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of results.
•5.Patients known to be allergic to the any of the components of the study medications.
•6.Patients who are receiving drugs which are known to affect hair growth.
•7.Patients with known malignancy.
•8.Refusal to participate in the study.

发起方

Hairrevive Centre for Hair Restoration Skin Rejuvenation